<DOC>
	<DOCNO>NCT00397826</DOCNO>
	<brief_summary>To collect lipid-lowering response data use simvastatin 40 mg tablet patient hypercholesterolemia .</brief_summary>
	<brief_title>Evaluation Effects Simvastatin 40mg</brief_title>
	<detailed_description>This open-label , prospective study investigate lipid-lowering efficacy sympathetic response normotensive hypercholesterolemia patient receive simvastatin 40 mg daily 3 month . The total duration study approximately 13 week , comprise 1-week ( 4 week ? ) screen period 12-week active treatment period . 20 hypercholesterolemia patient normal blood pressure enrol treatment group .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Male female patient , &gt; 18 year age Patients hypercholesterolemia meet follow lipid criterion : 1. primary cholesterolemia : total cholesterol &gt; =240 mg/dl ldlc &gt; = 160 mg/dl 2. secondary cholesterolemia ( patient cad , dm ) : ldlc &gt; =130 mg/dl The patient willing follow NCEP therapeutic lifestyle change ( tlc ) similar cholesterollowering diet throughout duration study Congestive heart failure ( NYHA class III IV ) , uncontrolled cardiac arrhythmia , unstable angina Hypertension ( base atp 3 guideline ) Taking potent lipidlowering agent Unstable diabetes ( hba1c &gt; 9 % ) newly diagnose ( within 3 month ) , change antidiabetes medication within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>